Chikungunya

PaxVax joins Chikungunya vaccine quest with NIH licensing deal

Add PaxVax to the list of companies vying to roll out the first Chikungunya vaccine. The California biotech has licensed a clinical-stage candidate from the National Institutes of Health and aims to take that prospect to market.
 
PaxVax licensed the phase 2 virus-like particle vaccine candidate, taking on the job of conducting more clinical trials, developing release assays and commercial manufacturing processes, and, eventually, launching the product, CEO Nima Farzan said in an interview.
 
Undefined

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
 
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.
 
Undefined

Científicos españoles desarrollaron vacuna contra chikungunya

Investigadores del español Consejo Superior de Investigaciones Científicas dicen haber desarrollado una vacuna contra el virus del chikunguña, enfermedad procedente de países tropicales y transmitida por el mosquito tigre, buscan financiación para llevar a cabo los ensayos clínicos.

Undefined

Polynésie: Le chikungunya tue une cinquième fois

35.000, c'est aujourd'hui le nombre de Polynésien touchés par le virus du chikungunya. Un virus qui n'en finit plus de se répandre dans l'archipel, touchant les îles les plus lointaines. A Tahiti, où la population est plus dense, l'épidémie fait des ravages et l'hôpital sature (le précédent bilan officiel, datant du 1er novembre, faisait état de 18.300 cas). 
Undefined

Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Vienna-based Themis Bioscience, and the Paris based Institut Pasteur announced earlier this week a successful phase I trial of their revolutionary chikungunya vaccine. The phase 1 trial of 42 subjects demonstrated the vaccine to be well tolerated and safe. The trial also revealed that the vaccine is clearly dose-dependant, and that even at very low doses the vaccine elicited neutralising antibodies in every participant.
 
Undefined

Themis Bioscience’s Vaccine against Chikungunya Successful in Phase 1

The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two international conferences. The vaccine candidate was developed under a R&D collaboration between Themis Bioscience GmbH and the Institut Pasteur (Paris, France) based upon a measles vaccine vector technology (Themaxyn®).
Undefined

Chikungunya vaccine protects against virus in small Phase I study

With recent outbreaks in the Caribbean and the Pacific, the U.S. Centers for Disease Control and Prevention (CDC) is concerned that the number of chikungunya cases among travelers will continue to rise. But results from an early-stage clinical trial point to a promising vaccine that may be able to prevent transmission of the disease.
 
In a Phase I clinical trial of 25 adult volunteers, the experimental vaccine showed protection against the virus, eliciting neutralizing antibodies in all participants, according to a study appearing Aug. 15 in The Lancet.
Undefined

Study shows effectiveness of experimental chikungunya vaccine

Researchers with the National Institute of Allergy and Infectious Diseases (NIAID) recently conducted a study that showed the effectiveness of an experimental vaccine to treat the chikungunya virus.
 
The results of the study, which showed the production of neutralizing antibodies in all 25 adult volunteers, were published in the current issue of the Lancet.
 
Read more here
Undefined

NIAID health officials warn of possible U.S. chikungunya threat

Health officials from the National Institute of Allergy and Infectious Diseases (NIAID) recently issued a warning about the potential for the emergence of the chikungunya virus in the U.S.
 
Undefined

Pages